Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

There is no established treatment for lung adenocarcinoma with uncommon/compound epidermal growth factor receptor (EGFR) mutations. We report a case of a 73-year-old man with stage IVB lung adenocarcinoma harboring E709G and L861Q EGFR mutations. After 2 months of afatinib treatment, significant tum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiratory medicine case reports 2024-01, Vol.51, p.102094, Article 102094
Hauptverfasser: Hirokawa, Hisanori, Hirata, Hirokuni, Azuma, Hayase, Sugitate, Kei, Soda, Sayo, Matsushima, Jun, Fukushima, Yasutsugu
Format: Artikel
Sprache:eng
Schlagworte:
afatinib
Case Report
E709G
EGFR
L861Q
Lung adenocarcinoma
Uncommon/compound mutation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There is no established treatment for lung adenocarcinoma with uncommon/compound epidermal growth factor receptor (EGFR) mutations. We report a case of a 73-year-old man with stage IVB lung adenocarcinoma harboring E709G and L861Q EGFR mutations. After 2 months of afatinib treatment, significant tumor shrinkage was observed, and the patient's condition remained stable for 1 year. This case highlights the potential effectiveness of afatinib for treating rare stage IV lung adenocarcinoma with these specific EGFR mutations.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2024.102094